Vaxcyte, Inc. (PCVX) Stock Price & How to Invest
Short answer
PCVX is Vaxcyte, a clinical-stage vaccine developer whose whole value rests on its next-generation pneumococcal conjugate vaccine VAX-31, so investing in it is a binary bet on Phase 3 data rather than on current sales. You can buy shares through any brokerage, but understand that it has no product revenue and a stock price that will move sharply on trial readouts.
PCVX stock price
As of 2026-07-08, Vaxcyte, Inc. (PCVX) last closed at $58.71, up 64.1% over the past year. Over the past 52 weeks it has traded between $29.67 and $63.04.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Vaxcyte, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Vaxcyte, Inc. (PCVX) do?
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine company built around a proprietary cell-free protein synthesis platform that it uses to design broad-spectrum conjugate vaccines against bacterial disease. Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in adults, which covers more serotypes than currently marketed shots from Pfizer and Merck. As of Q1 2026 the company had fully enrolled its three adult Phase 3 OPUS trials (about 6,191 adults dosed), with topline OPUS-1 data expected in Q4 2026 and OPUS-2 and OPUS-3 in the first half of 2027, plus an earlier-stage infant program and other pipeline candidates such as VAX-A1.
The investment picture is a classic high-stakes biotech setup: no approved products and therefore no product revenue, funded instead by a large cash balance (about $2.74 billion at March 31, 2026) that management has repeatedly topped up through equity raises. Operating losses run in the hundreds of millions per quarter as the company funds late-stage trials and manufacturing scale-up. The upside case is that VAX-31 wins share in a pneumococcal vaccine market analysts size at well over $10 billion later this decade; the downside case is a disappointing Phase 3 readout or competitive pressure from entrenched players, either of which could sharply reset the valuation. Walnut is not an investment adviser, and this page is descriptive rather than a recommendation.
What's driving Vaxcyte, Inc. (PCVX)?
1. VAX-31 Phase 3 readouts
The central catalyst is the OPUS Phase 3 program for the 31-valent adult pneumococcal vaccine, which is fully enrolled with roughly 6,191 adults dosed. Topline OPUS-1 data is expected in Q4 2026, with OPUS-2 and OPUS-3 following in the first half of 2027. These readouts will largely determine whether Vaxcyte has a commercial-scale product or a stalled program.
2. Broader serotype coverage as a wedge
VAX-31 targets 31 serotypes, more than Pfizer's Prevnar 20 or Merck's 21-valent Capvaxive, and a prior Phase 2 result was viewed by some analysts as a strong showing against Prevnar 20. If that breadth translates into a differentiated label, it could support share gains in a large, established adult vaccine category.
3. Platform and pipeline optionality
The company's cell-free protein synthesis platform is meant to be reusable across multiple conjugate and protein vaccines, including an infant pneumococcal program and earlier candidates such as VAX-A1 (Group A Strep). Success with VAX-31 would validate the platform and give the pipeline additional shots on goal beyond the lead asset.
4. Strong balance sheet funding the runway
With about $2.74 billion in cash, equivalents and investments as of March 31, 2026, bolstered by a February 2026 equity offering, Vaxcyte is well funded to reach its key readouts. That cash cushion reduces near-term financing risk even as the company burns through several hundred million dollars per quarter.
What are the risks to Vaxcyte, Inc. (PCVX)?
Vaxcyte is pre-revenue and unprofitable, so the equity is highly sensitive to binary clinical outcomes; a weak VAX-31 Phase 3 result could sharply cut the valuation. The company posted a Q1 2026 net loss of about $320.6 million and continues to burn cash, meaning further equity raises and shareholder dilution are likely over time. It faces entrenched, deep-pocketed competitors (Pfizer, Merck, GSK and Sanofi) with established commercial and payer relationships that could limit uptake even if VAX-31 is approved. Regulatory timelines, potential FDA scrutiny, and manufacturing scale-up all add execution risk. Because valuation is driven almost entirely by future expectations rather than current earnings, the stock can be volatile around data and news.
How is Vaxcyte, Inc. (PCVX) valued? (approximate, MAY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Vaxcyte, Inc.'s investor relations page or your broker.
- Product revenue (TTM): ~$0 (clinical-stage, no approved products)
- Q1 2026 net loss: ~$320.6M
- Q1 2026 R&D expense: ~$312.8M
- Cash & investments: ~$2.74B (Mar 31, 2026)
- Shares outstanding: ~144.3M
- Market cap: ~$8.4B (Jul 2026)
As a clinical-stage biotech, Vaxcyte has no product revenue and cannot be valued on earnings or standard multiples; its market cap reflects the probability-weighted value of VAX-31 and the pipeline. The roughly $2.74 billion cash balance is a large share of the market cap and funds operations through the key Phase 3 readouts. Quarterly losses in the $300 million range and periodic equity raises mean per-share dilution is an ongoing feature of the story.
Who competes with Vaxcyte, Inc. (PCVX)?
Large-cap pneumococcal incumbents
Pfizer (Prevnar 20 and Prevnar 13) and Merck (Vaxneuvance and the 21-valent Capvaxive, approved in 2024) dominate the pneumococcal conjugate vaccine market with approved products, established manufacturing and deep payer relationships. They are Vaxcyte's most direct commercial competitors and set the coverage bar VAX-31 must beat.
Broader vaccine majors
GSK and Sanofi are major vaccine developers with global commercial reach and adjacent respiratory and pneumococcal programs. Even where they are not head-to-head today, their scale and pipelines make them credible long-term rivals in the adult vaccine category Vaxcyte is targeting.
Clinical-stage vaccine platforms
Other pre-revenue biotechs pursuing conjugate vaccines or novel platform approaches compete with Vaxcyte for scientific validation, trial talent and investor capital. None has VAX-31's late-stage position in high-valency pneumococcal, but the group represents the broader innovation risk to the platform thesis.
How to invest in Vaxcyte, Inc. (PCVX)
There are three common ways to get PCVX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PCVX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PCVX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Vaxcyte, Inc. (PCVX)
PCVX is a cash-rich, pre-revenue biotech whose story is dominated by the upcoming VAX-31 Phase 3 readouts, which makes it high-variance rather than a steady compounder.
More on Vaxcyte, Inc. (PCVX)
Whether PCVX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PCVX a buy?, and where the stock could go from here in the PCVX stock forecast.
For income investors, whether PCVX pays a dividend and how the payout looks is covered in does PCVX pay a dividend?
Build a basket around PCVX with Walnut
Use Vaxcyte, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Vaxcyte (PCVX) do?
+
Vaxcyte is a clinical-stage vaccine company that uses a cell-free protein synthesis platform to design broad-spectrum conjugate vaccines against bacterial infections. Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine for adults.
Does Vaxcyte have any revenue or profit?
+
No. As of 2026 Vaxcyte has no approved products and therefore essentially no product revenue, and it is not profitable. It reported a Q1 2026 net loss of about $320.6 million and funds itself from cash raised in equity offerings.
What is VAX-31 and why does it matter?
+
VAX-31 is Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, covering more serotypes than current adult vaccines from Pfizer and Merck. It is the company's most valuable asset, so its Phase 3 OPUS trial results largely drive the investment case.
When are the key VAX-31 data readouts?
+
As of Q1 2026 the three adult OPUS Phase 3 trials were fully enrolled. Topline OPUS-1 data is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in the first half of 2027.
How much cash does Vaxcyte have?
+
Vaxcyte reported about $2.74 billion in cash, cash equivalents and investments as of March 31, 2026, helped by a February 2026 equity raise. That balance is meant to fund operations through its major clinical readouts.
Who are Vaxcyte's main competitors?
+
Its most direct competitors are Pfizer (Prevnar 20 and Prevnar 13) and Merck (Vaxneuvance and the 21-valent Capvaxive). GSK and Sanofi are broader vaccine majors that could compete over the longer term in the adult vaccine market.
What are the biggest risks with PCVX?
+
The main risks are a disappointing VAX-31 Phase 3 readout, ongoing cash burn and likely future dilution, competition from entrenched, larger vaccine makers, and regulatory or manufacturing delays. Because there are no current earnings, the stock can be volatile around clinical news.
How can I invest in PCVX?
+
PCVX trades on the Nasdaq and can be bought through any standard brokerage account, including one connected to Walnut. Walnut is not an investment adviser, so this information is descriptive and you should do your own research or consult a licensed professional before investing.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Vaxcyte, Inc.'s investor relations page or your broker before making investment decisions.